Utility of Genomic Profiling Use for Targeted Therapy in a Phase I Setting Reveals that ESCAT I/II Actionable Targets are Associated with Improved Outcomes By Ogkologos - May 6, 2025 829 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CoPPO study Source RELATED ARTICLESMORE FROM AUTHOR Perioperative Durvalumab Plus FLOT Improves OS in Patients with Resectable Gastric or GEJ Adenocarcinoma Advancing Childhood Cancer Research: A Conversation with Dr. Brigitte Widemann Azacitidine-Venetoclax Prolongs EFS Over Induction Chemotherapy Among Induction-Eligible Patients with AML MOST POPULAR Concurrent Chemoradiotherapy Followed by Adjuvant Cisplatin-Gemcitabine for the Treatment of Patients... June 15, 2023 Nivolumab Plus Ipilimumab Demonstrates Long-Term Survival Benefit in Patients with Advanced... May 28, 2024 Five Questions With…Sharon. May 12, 2022 People who’ve had radiotherapy shape our new policy calls May 4, 2023 Load more HOT NEWS FDA Approves Gedatolisib with Fulvestrant, With or Without Palbociclib, for HR-positive,... First-Line Encorafenib, Binimetinib, and Cetuximab Combination Provides Clinical Benefit and Manageable... EMA Recommends Granting a Marketing Authorisation for Capmatinib 49-Year-Old Breast Cancer Patient Grateful She Didn’t Wait Until 50 for...
